 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Topiramate | Cas: | 97240-79-4 |
|---|---|---|---|
| Mf: | C12H21NO8S | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | Antiepileptic Drug Topiramate Powder,97240-79-4 Topiramate Powder,99% Purity Topiramate Powder |
||
Factory Supply Topiramate Antiepileptic Drug with Best Price CAS 97240-79-4 Topiramate 99%
| Product name | Topiramate |
| CAS NO | 97240-79-4 |
| MF | C12H21NO8S |
| MW | 339.36 |
| EINECS | 200-659-6 |
| Appearance | White Powder |
| Usage | 1. anticonvulsant, antimigraine, GABA-A agonist, AMP/kinate glutamate receptor antagonist, carbonic anhydrase inhibitor. 2. Used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. |
Topiramate Description:
Topiramate (the TPM) is a naturally existing monosaccharide D-fructose sulfide, and together with felbamate, lamotrigine and vigabatrin are current several broad-spectrum anti-epileptic drugs with relatively wide clinical application and can be used to control different types of epilepsy with excellent efficacy and pharmacokinetics.
This product is generally used for the adjuvant treatment of antiepileptic drugs and is effective in treating simple and complex seizures as well as systemic tonic-clonic seizures and can also be used for the treatment of infantile spasms. Features of this product include excellent long-term efficacy, no significant resistance as well as being able to be used alone for antiepileptic purpose.
But in cases of being applied to children or fast increase of the amount can cause cognitive impairment and neurotoxicity, and easy to trigger kidney stones.
Topiramate Ptoduct Application:
In 1980, scientists had first successfully synthesized topiramate in the laboratory. It had been applied to patients with epilepsy for the first time in 1986. In 1995, it was approved for entering into the market of UK for the first time. Its basic structure is fructopyranose sulfamate. Unlike other kinds of anti-epileptic drug, TPM has various kinds of anti-epileptic mechanisms including blocking the voltage-dependent sodium channels, enhancing the activity of GABA in the location of the γ- aminobutyric acid A (GABAA) receptor as well as blocking the activity of the AMPA glutamate receptor. In addition, there is still mild effect of carbonic anhydrase inhibitors.
Europe and the United States had conducted double-blind, placebo-controlled studies and demonstrated that the adjunctive therapy with topiramate has excellent efficacy, safety and is well tolerated in the treatment of various types of refractory epilepsy. Now it has begun with topiramate monotherapy and has also achieved good results with 62% of patients with epileptic seizures disappearing completely.
Contact Person: July
Tel: 25838890
